Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) EPS (Basic) (2024 - 2026)

Prelude Therapeutics' EPS (Basic) history spans 3 years, with the latest figure at -$0.13 for Q1 2026.

  • On a quarterly basis, EPS (Basic) rose 69.05% to -$0.13 in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.0, a 40.83% increase, with the full-year FY2025 number at -$1.29, up 23.21% from a year prior.
  • EPS (Basic) hit -$0.13 in Q1 2026 for Prelude Therapeutics, up from -$0.2 in the prior quarter.
  • Over the last five years, EPS (Basic) for PRLD hit a ceiling of -$0.13 in Q1 2026 and a floor of -$0.46 in Q2 2024.
  • Historically, EPS (Basic) has averaged -$0.35 across 3 years, with a median of -$0.41 in 2025.
  • Biggest five-year swings in EPS (Basic): changed 0.0% in 2025 and later skyrocketed 69.05% in 2026.
  • Tracing PRLD's EPS (Basic) over 3 years: stood at -$0.38 in 2024, then soared by 47.37% to -$0.2 in 2025, then soared by 35.0% to -$0.13 in 2026.
  • Business Quant data shows EPS (Basic) for PRLD at -$0.13 in Q1 2026, -$0.2 in Q4 2025, and -$0.26 in Q3 2025.